TW202428307A - 包含胜肽、界面活性劑及聚合物的組成物 - Google Patents

包含胜肽、界面活性劑及聚合物的組成物 Download PDF

Info

Publication number
TW202428307A
TW202428307A TW112138775A TW112138775A TW202428307A TW 202428307 A TW202428307 A TW 202428307A TW 112138775 A TW112138775 A TW 112138775A TW 112138775 A TW112138775 A TW 112138775A TW 202428307 A TW202428307 A TW 202428307A
Authority
TW
Taiwan
Prior art keywords
group
meth
peptide
composition
alkyl
Prior art date
Application number
TW112138775A
Other languages
English (en)
Chinese (zh)
Inventor
坂口真菜
岩田智哉
真貝太規
Original Assignee
日商中外製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2022/038128 external-priority patent/WO2023063376A1/ja
Application filed by 日商中外製藥股份有限公司 filed Critical 日商中外製藥股份有限公司
Publication of TW202428307A publication Critical patent/TW202428307A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08—Cellulose derivatives
    • C08L1/26—Cellulose ethers
    • C08L1/28—Alkyl ethers
    • C08L1/284—Alkyl ethers with hydroxylated hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08—Cellulose derivatives
    • C08L1/32—Cellulose ether-esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Detergent Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Cosmetics (AREA)
TW112138775A 2022-10-12 2023-10-11 包含胜肽、界面活性劑及聚合物的組成物 TW202428307A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
PCT/JP2022/038128 WO2023063376A1 (ja) 2021-10-13 2022-10-12 ペプチド化合物及び界面活性剤を含む組成物
WOPCT/JP2022/038128 2022-10-12
EP22200995.3 2022-10-12
EP22200995.3A EP4166133B1 (en) 2021-10-13 2022-10-12 Composition containing peptide compound and surfactant
JP2022-211372 2022-12-28
JP2022211372 2022-12-28
JP2023068715 2023-04-19
JP2023-068715 2023-04-19

Publications (1)

Publication Number Publication Date
TW202428307A true TW202428307A (zh) 2024-07-16

Family

ID=90669612

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112138775A TW202428307A (zh) 2022-10-12 2023-10-11 包含胜肽、界面活性劑及聚合物的組成物

Country Status (5)

Country Link
EP (1) EP4582092A1 (https=)
JP (1) JPWO2024080308A1 (https=)
CN (1) CN120091828A (https=)
TW (1) TW202428307A (https=)
WO (1) WO2024080308A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026004834A1 (ja) * 2024-06-25 2026-01-02 中外製薬株式会社 固体分散体、及びそれを含む組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2046830C (en) * 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
JP4711520B2 (ja) * 2000-03-21 2011-06-29 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
KR20120039763A (ko) * 2004-06-08 2012-04-25 버텍스 파마슈티칼스 인코포레이티드 약학 조성물
US8093207B2 (en) * 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
JP5149585B2 (ja) * 2007-10-02 2013-02-20 浜松ホトニクス株式会社 微粒子分散液製造方法
AU2012271691A1 (en) * 2011-06-14 2014-01-16 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
EP2802314B1 (en) * 2012-01-13 2020-11-25 XSpray Microparticles AB A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
CN104853749A (zh) * 2012-09-17 2015-08-19 塔瑞克斯制药有限公司 血管紧张素的口服制剂
HUP1500055A1 (hu) * 2015-02-09 2016-08-29 Druggability Technologies Ip Holdco Ltd Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények
PE20221323A1 (es) 2019-11-07 2022-09-09 Chugai Pharmaceutical Co Ltd Compuesto de peptidos ciclicos que tiene accion inhibidora de kras
MX2022014886A (es) * 2020-05-29 2023-01-04 Seagen Inc Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab y una quimioterapia a base de oxaliplatino.
WO2022094816A1 (en) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Solid formulation
TW202309065A (zh) 2021-05-07 2023-03-01 日商中外製藥股份有限公司 包含n-取代胺基酸殘基之環狀化合物的製造方法

Also Published As

Publication number Publication date
JPWO2024080308A1 (https=) 2024-04-18
EP4582092A1 (en) 2025-07-09
WO2024080308A1 (ja) 2024-04-18
CN120091828A (zh) 2025-06-03

Similar Documents

Publication Publication Date Title
CA2338256C (en) Bioenhanced formulations comprising eprosartan in oral solid dosage form
KR102024955B1 (ko) 치환된 시클로부텐디온 항염 화합물의 콜린 염
HRP20020182A2 (en) Benzamide formulation with histone deacetylase inhibitor activity
JPH04234817A (ja) オメプラゾールの直腸投与組成物
CN102369009B (zh) 依曲韦林和烟酰胺的共晶体
TW200303204A (en) Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
JP2003514019A (ja) カルベジロールメタンスルホン酸塩
CS417791A3 (en) Capsules or tablets with a controlled release
TW202428307A (zh) 包含胜肽、界面活性劑及聚合物的組成物
JP7247122B2 (ja) ベリノスタットの新規経口製剤
JPH03130225A (ja) 易吸収性製剤用組成物
KR20070068658A (ko) 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
WO2025003956A1 (en) High drug loading formulations of encorafenib
Zhang et al. Comparative Evaluation of Particle Size Reduction, Salt Formation, and Amorphous Formulation on the Biopharmaceutical Performance of a Weak Base Drug Candidate
AU739295B2 (en) Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation
JPH08301789A (ja) 活性化合物の調節された放出性を有する製剤およびそれらの製造方法
HK40120690A (zh) 含有肽、表面活性剂和聚合物的组合物
JPWO2011081118A1 (ja) 経口投与用医薬組成物
WO2025220686A1 (ja) ペプチド、糖脂肪酸エステル構造を有する界面活性剤及び（メタ）アクリル酸系ポリマーを含む医薬組成物
CN116234539A (zh) 血栓素受体拮抗剂调配物
JP2004035535A (ja) 非ステロイド系抗炎症薬剤を含む経口医薬組成物及びその製造方法
JP2011153135A (ja) タルチレリン製剤およびタルチレリン製剤の溶出性維持方法
TW202440065A (zh) 包含分散對象物質的固體分散體、包含其之醫藥組合物及其製造方法
WO2025037251A1 (en) Solid dispersions of niraparib or a pharmaceutically acceptable salt thereof
AU2024303437A1 (en) Solid dispersion of p2x4 inhibitor, and preparation method therefor and use thereof